Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$19.4 - $28.71 $7.25 Million - $10.7 Million
-373,500 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$24.2 - $35.76 $968,000 - $1.43 Million
40,000 Added 11.99%
373,500 $9.71 Million
Q3 2020

Nov 13, 2020

BUY
$31.18 - $52.71 $1.4 Million - $2.37 Million
45,000 Added 15.6%
333,500 $12.4 Million
Q2 2020

Aug 14, 2020

BUY
$30.04 - $51.31 $3 Million - $5.13 Million
100,000 Added 53.05%
288,500 $14.8 Million
Q2 2019

Aug 15, 2019

BUY
$40.1 - $52.33 $200,500 - $261,650
5,000 Added 2.72%
188,500 $8.77 Million
Q1 2019

May 15, 2019

BUY
$40.11 - $53.57 $3.35 Million - $4.47 Million
83,500 Added 83.5%
183,500 $7.37 Million
Q3 2018

Nov 14, 2018

BUY
$40.74 - $51.41 $3.43 Million - $4.32 Million
84,100 Added 528.93%
100,000 $4.44 Million
Q2 2018

Aug 14, 2018

SELL
$36.2 - $76.4 $325,800 - $687,600
-9,000 Reduced 36.14%
15,900 $623,000
Q1 2018

May 09, 2018

BUY
$65.94 - $80.76 $791,280 - $969,120
12,000 Added 93.02%
24,900 $1.8 Million
Q4 2017

Feb 14, 2018

BUY
$43.47 - $67.43 $560,763 - $869,847
12,900
12,900 $849,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $179M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Bamco Inc Portfolio

Follow Bamco Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bamco Inc , based on Form 13F filings with the SEC.

News

Stay updated on Bamco Inc with notifications on news.